Microbot Medical Inc. (NASDAQ:MBOT) Stock Now Rated “Hold” by Sell-Side Brokerages

Microbot Medical Inc. (NASDAQ:MBOT) has received an average rating of “Hold” from the five research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.38.

Several research firms recently commented on MBOT. B. Riley Financial initiated coverage on shares of Microbot Medical in a research report on Friday, September 11th. They set a “buy” rating and a $4.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, October 2nd. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Microbot Medical in a research report on Wednesday. Wall Street Zen raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. Finally, Zacks Research downgraded shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th.

Microbot Medical Price Performance

Shares of MBOT stock opened at $0.94 on Friday. The business’s 50-day moving average price is $1.30 and its 200-day moving average price is $1.72. Microbot Medical has a 12 month low of $0.93 and a 12 month high of $2.85.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. Analysts predict that Microbot Medical will post -0.30 earnings per share for the current year.

Institutional Trading of Microbot Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CTC Alternative Strategies Ltd. bought a new position in Microbot Medical during the 1st quarter worth $28,000. Bank of America Corp DE lifted its holdings in Microbot Medical by 1,688.1% during the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock worth $183,000 after buying an additional 71,560 shares during the period. Cetera Investment Advisers lifted its holdings in Microbot Medical by 44.7% during the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after buying an additional 13,099 shares during the period. Private Advisor Group LLC bought a new stake in shares of Microbot Medical in the 1st quarter valued at about $54,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Microbot Medical in the 4th quarter valued at about $65,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company developing robotic and computer-assisted technologies for minimally invasive endovascular procedures. The company focuses on systems intended to help physicians navigate blood vessels and deliver interventional devices while potentially improving procedural control and reducing radiation exposure to medical personnel.

Microbot Medical’s primary product candidate is the LIBERTY Endovascular Robotic System, a single-use, disposable robotic platform designed to remotely control guidewires and catheters during vascular procedures.